Online inquiry

IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13107MR)

This product GTTS-WQ13107MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ACVRL1 gene. The antibody can be applied in Hepatocellular carcinoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000020.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 94
UniProt ID P37023
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13107MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3878MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ2792MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG-282
GTTS-WQ5695MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ9733MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ12836MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ13899MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-2176
GTTS-WQ2041MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ7427MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GBR500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW